

## Hikma and CanariaBio sign exclusive licensing agreement to bring Oregovomab to the Middle East and North Africa

**London, 10 October 2023** – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces an exclusive license agreement with CanariaBio, a Korean biopharmaceutical company focused on the development and commercialization of immunotherapies for cancer. Under the terms of the agreement, Hikma has an exclusive license to commercialise Oregovomab in 18 Middle East and North Africa (MENA) countries.

Oregovomab is a murine monoclonal antibody and a first-in-class anti-CA125 immunotherapy drug candidate. It is being tested in combination with carboplatin and paclitaxel for patients with advanced ovarian cancer. Oregovomab has obtained Orphan Drug Designations from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

“Ovarian cancer is ranked as the eighth most common cancer in women globally<sup>1</sup> and the first-line treatment for this disease has not changed for many years. We have been actively expanding our oncology portfolio through R&D and in-licensing, in order to address unmet medical needs in different types of cancer and bring renewed hope to cancer patients in the MENA region,” said Mazen Darwazah, Hikma’s Executive Vice Chairman and President of MENA. “We believe Oregovomab can potentially improve the treatment outcomes for patients with advanced primary ovarian cancer. We are excited about the collaboration with CanariaBio as it will bring hope to our cancer patients in MENA and strengthen our oncology portfolio.”

### About Oregovomab

Oregovomab is a murine monoclonal antibody direct to the tumour-associated antigen CA125 that stimulates a host cytotoxic immune response against tumour cells expressing CA 125, a biomarker commonly found in ovarian cancer (OC). In a randomized Phase II clinical trial, oregovomab demonstrated a significant improvement in progression-free and overall survival in advanced OC treatment when administered simultaneously with first-line chemotherapy. Oregovomab yielded a median progression-free survival of 41.8 months compared with 12.2 months with standard chemotherapy (HR, 0.46, P=0.0027). This promising schedule is currently investigated in a phase III trial.

- ENDS -

### Enquiries

Hikma Pharmaceuticals PLC

Susan Ringdal  
EVP, Strategic Planning and Global Affairs

+44 (0)20 7399 2760/ +44 7776 477050  
uk-investors@hikma.uk.com

Mona Abdallah  
Senior Director, MENA Communications

+ 962 6 5802900  
MBAbdallah@Hikma.com

<sup>1</sup> World Cancer Research Fund International, available at <https://www.wcrf.org/cancer-trends/ovarian-cancer-statistics/#:~:text=Latest%20ovarian%20cancer%20data.of%20ovarian%20cancer%20in%202020>



### **About Hikma**

(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated BBB-/stable S&P and BBB-/positive Fitch)

Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,800 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: [www.hikma.com](http://www.hikma.com)

### **About CanariaBio Inc.**

CanariaBio Inc. is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of innovative cancer biotherapeutics. CanariaBio's technology platform includes a portfolio of tumor antigen-specific monoclonal antibodies targeting CA-125, MUC1, PSA, and Her2/neu. For more information, visit CanariaBio's website at [www.canariabio.com](http://www.canariabio.com).